BJMO - 2021, issue 3, march 2021
Hannah Van Belle , Hans Wildiers
Background: Docetaxel, carboplatin and trastuzumab, with or without pertuzumab (TCH(P)), is increasingly used for (neo) adjuvant treatment of HER2-positive early breast cancer. However, its associated febrile neutropenia (FN) risk is unclear: pivotal studies reported FN risks <10%, but in clinical practice a high FN rate (>20%) was observed. This systematic review and meta-analysis determine the FN risk associated with TCH(P) and the effect of primary prophylactic granulocyte colony-stimulating factor (PP G-CSF).
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
